EUCTR2005-002421-31-DE进行中（未招募）不适用
A phase II randomised, double-blind, multicenter, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently taking methotrexate. - Efficacy, safety and tolerability of AD 452 in patients wih RA
Arakis Ltd.0 个研究点目标入组 292 人开始时间: 2005年11月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 292
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects will be considered eligible if they meet all of the following criteria at the Screening Visit:
- •- Male or female subjects aged =18 years to =75 years.
- •- Subjects with a documented diagnosis of adult rheumatoid arthritis according to the revised criteria of the American College of Rheumatology (ACR) – ACR functional classes I-III. Onset must be after age 16 years and duration must have been at least 6 months.
- •- Subjects must have 4 or more tender or painful joints and 4 or more swollen joints (28 joint count) and CRP greater than or equal to 4mg/L.
- •- Subjects must be taking MTX (po, sc, im) with a weekly dose in the range of 10-25 mg/week or 7.5 mg if a higher dose was not tolerated. MTX therapy must have been present for 6 months and the dose must have been stable for the last 8 weeks.
- •- The dose of any other medical therapy for RA (NSAID, COX2, codeine, low dose glucocorticoid (=10mg prednisolone equivalent)) must have been stable for at least 4 weeks.
- •- Subjects who are able to understand the nature of the study, comply with the protocol for the duration of the study and give written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects will be ineligible if they meet any of the following criteria:
- •- Subjects with a history of other inflammatory joint disease, e.g., mixed connective tissue disorder, seronegative spondylarthropathy, psoriatic arthritis, Reiter’s syndrome, systemic lupus erythematosus (SLE), sarcoidosis, synoviorthesis or any arthritis with onset prior to 16 years of age.
- •- Subjects who are pregnant or breast-feeding. Women of child-bearing potential (including, for example, women who are less than 24 months postmenopausal who have not had hysterectomy or tubal ligation) must be willing and able to use an adequate method of contraception during the course of the study or to practice sexual abstinence and must have a negative pregnancy test prior to receiving study drug.
- •- Subjects with a change in anti-rheumatic medication (NSAID, COX2, codeine, low dose glucocorticoid) within 4 weeks of the Screening Visit
- •- Subjects who are on glucocorticoid >10mg prednisolone equivalent or who have been treated with or have planned treatment with depot corticosteroids (including intraarticular or intrasynovial) within 4 weeks of the Screening Visit.
- •- Subjects who are currently taking or who have taken any investigational drug within 3 months prior to the screening visit (previous participation in protocol P-AD452-019 is acceptable).
- •- Subjects who require treatment with any other known disease modifying therapy; or halofantrine or mefloquine.
- •- Subjects with QTc >470ms at baseline.
- •- Subjects with a known allergy to the study drugs or any of their components.
- •- Subjects with a presence of any of the following concurrent conditions:
- •- Diabetes mellitus (insulin dependent or difficult to control)
- •- History of / or current therapy for lymphoma, leukemia or malignant melanoma
- •- Active infection
- •- Known HIV, hepatitis B or hepatitis C positive serology
- •- History of cardiac conduction disorders (not including grade 1 AV block or incomplete right or left bundle branch block) or uncontrolled hypertension
- •- Significant hepatic or renal insufficiency (any of the transaminases >2 x upper limit of normal, creatinine > 1.5 x upper limit of normal)
- •- Evidence or history of alcohol or drug abuse
- •- Clinically significant abnormal screening laboratory values (not including CRP)
- •- Hemoglobin <8 g/dcl
- •- A history of sensitivity to antimalarial or related compounds
- •- Active depression or a recent history of depression, generalised anxiety disorder, psychosis or schizophrenia or other major psychiatric disorders or convulsions
- •- Subjects who are unable or unwilling to comply fully with the protocol.
- •- Subjects who have previously entered this study.
- •- Subjects whom the investigator believes to be medically unfit to receive the study treatment, or unsuitable for any other reason.
- •- Subjects who have taken drugs on the following table for which the minimum washout period has not elapsed.
研究者
相似试验
进行中（未招募）
不适用
A phase II randomized, double-blind, multicentre, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adult subjects with active rheumatoid arthritis who are currently taking methotrexateLevel: PTClassification code 10039073Rheumatoid arthritisEUCTR2005-002421-31-GBArakis Ltd292
进行中（未招募）
不适用
A phase II multicenter, randomised, double-blind, parallel group, placebo-controlled, study to evaluate the effectiveness of EVT 302 in smoking cessation, effect on its own and in combination with open label nicotine replacementMale or female subjects who are chronic smokers, but motivated to quit smoking will be recruited.EUCTR2008-002472-99-DEEvotec Neurosciences GmbH
进行中（未招募）
1 期
Study of efficacy and safety of Rifamycin SV-MMX¿ 600 mg tablets administered three or two times daily versus Placebo to patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)Diarrhoea-predominant irritable bowel syndrome (IBS-D)MedDRA version: 20.1Level: PTClassification code 10023003Term: Irritable bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2016-004977-42-ITCOSMO TECHNOLOGIES LTD342
进行中（未招募）
1 期
Study of efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or two times daily versus Placebo to patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)Diarrhoea-predominant irritable bowel syndrome (IBS-D)MedDRA version: 20.1Level: PTClassification code 10023003Term: Irritable bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2016-004977-42-DECosmo Technologies Ltd.342
进行中（未招募）
1 期
Study of efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or two times daily versus Placebo to patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)Diarrhoea-predominant irritable bowel syndrome (IBS-D)MedDRA version: 20.1Level: PTClassification code 10023003Term: Irritable bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2016-004977-42-BECosmo Technologies Ltd.342